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Low Adherence to Outpatient Preoperative
Methicillin-Resistant Staphylococcus aureus
Decolonization Therapy
To the Editor—Evidence supports methicillin-resistant Staph-
ylococcus aureus (MRSA) decolonization with topical anti-
microbial and antiseptic agents to prevent infections in select
patient groups.1-5 While therapy effectiveness is heavily im-
pacted by adherence, there is a lack of data on patient-
reported adherence to such therapy.4,6,7 Here we report out-
patient adherence to preoperative MRSA decolonization
therapy obtained from nursing-administered surveys.
In 2006, the Providence Veterans Affairs Medical Center
implemented a preoperative MRSA colonization surveillance
and decolonization program. MRSA nares screening was con-
ducted during surgical scheduling appointments from Jan-
uary 2006 to December 2009. Patients were provided 15
minutes of nursing education on MRSA, what to anticipate
if MRSA-positive, appropriate decolonization therapy appli-
cation techniques, and date-specific time lines featuring day-
by-day instructions for use prior to surgery.
Surgical Service nurse practitioners contacted MRSA-
colonized outpatients a minimum of 7 days prior to surgery
to notify them of their screening results, to remind them they
would be receiving the decolonization package in the mail or
remind them to pick it up from the pharmacy, and to review
application techniques and time lines for use. The decolo-
nization regimen was prescribed as follows: mupirocin 2%
ointment to both nares twice daily for 5 days prior to surgery
and use of hexachlorophene 3% or chlorhexidine gluconate
4% body wash once daily for 3 days prior to surgery.
On the day of surgery, patients were rescreened and ad-
ministered adherence surveys by nursing to ascertain the
number of days each therapy was applied. Proportion of days
covered (PDC) was calculated as the number of days therapy
was applied, divided by the number of prescribed days of
therapy. Complete adherence to the decolonization regimen
was defined as a PDC of 1.0 for both mupirocin (5/5 days)
and body wash (3/3 days). Colonization persistence was de-
fined as a positive nares culture on the day of surgery. Post-
operative MRSA infections were identified from positive clin-
ical cultures in addition to a physician diagnosis of infection
and/or nursing notes describing clinical signs of infection in
the 30 days following surgery. We assessed differences in col-
onization persistence and postoperative MRSA infections at
different PDC levels with x2 and Fisher exact tests as appro-
priate.
Mupirocin susceptibilities were available for a sample of
the MRSA-positive preoperative nares screening isolates, and
resistance was defined as low level (minimum inhibitory con-
centration, 8–128 mg/L) or high level (≥256 mg/L) according
to previously described methods.8 We assessed PDC temporal
trends by using nonparametric Spearman rank correlation.
All analyses were performed using SAS, version 9.1.3 (SAS
Institute). This study was reviewed and approved by the In-
stitutional Review Board.
Of the 45 MRSA-colonized outpatients who received the
preoperative decolonization kit, 62.2% applied mupirocin to
their nares as instructed for 5 days prior to their scheduled
surgery (Table 1). Body wash was applied for 3 days by 46.7%
of patients. Most patients were male (1 female), with a mean
age of 57 years (standard deviation, 19). Surgery types in-
cluded various noncardiothoracic surgeries, the majority of
which were orthopedic, vascular, urological, hernia repairs,
or tumor resections.
Complete adherence to the decolonization regimen was
reported by 31.1% of patients (Table 1). The most common
patient-reported reason for incomplete adherence related to
recall, as several patients could not remember whether and
when they applied each topical therapy. Five (11.1%) patients
developed a postoperative MRSA infection in the 30 days
following surgery, and 17 (37.8%) patients were still colonized
on the day of surgery. Colonization persistence and 30-day
MRSA infections did not vary significantly by PDC (P ≥
for all comparisons; Table 1). Body wash PDC decreased.10
significantly over the study period ( ). No temporalP ! .03
trends were observed in mupirocin PDC, adherence to both
mupirocin and body wash, colonization persistence, or MRSA
infections.
Mupirocin susceptibilities of preoperative nares screening
isolates were available for 40.0% (18/45) of patients. Five
(27.8%) of the available isolates were mupirocin resistant (4
high level, 1 low level). Four of 5 patients with mupirocin-
resistant isolates were still colonized on the day of surgery (3
high level, 1 low level). Only 1 patient with mupirocin-
resistant MRSA (high level) developed a MRSA infection in
the 30 days following surgery. This patient was 100% adherent
to mupirocin, with 0% adherence to body wash. When pa-
tients colonized with mupirocin-resistant MRSA were ex-
cluded, no differences were observed in colonization persis-
tence or follow-up MRSA infections by PDC.
Nearly two-thirds of patients completed mupirocin therapy
as instructed, while only one-third were fully adherent to both
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table 1. Methicillin-Resistant Staphylococcus aureus (MRSA) Decolonization Therapy: Proportion of
Days Covered (PDC), Colonization Persistence, and Postoperative MRSA Infections
Mupirocin Body wash Mupirocin and body wash
Mean PDC (SD) 0.8 (0.3) 0.7 (0.4) ...
Median PDC (IQR) 1.0 (0.6–1.0) 0.7 (0.3–1.0) ...
PDC p 1.0a 28 (62.2) 21 (46.7) 14 (31.1)
Colonized on day of surgery 8 (28.6) 9 (42.9) 5 (35.7)
30-day postoperative MRSA infection 3 (10.7) 2 (9.5) 1 (7.1)
PDC ≥ 0.8b 30 (66.7) 21 (46.7) 16 (35.6)
Colonized on day of surgery 9 (30.0) 9 (42.9) 6 (37.5)
30-day postoperative MRSA infection 4 (13.3) 2 (9.5) 2 (12.5)
PDC ≥ 0.7c 30 (66.7) 28 (62.2) 19 (42.2)
Colonized on day of surgery 9 (30.0) 10 (35.7) 6 (31.6)
30-day postoperative MRSA infection 4 (13.3) 3 (10.7) 3 (15.8)
PDC ≥ 0.6d 37 (82.2) 28 (62.2) 25 (55.6)
Colonized on day of surgery 12 (32.4) 10 (35.7) 8 (32.0)
30-day postoperative MRSA infection 4 (10.8) 3 (10.7) 3 (12.0)
note. Data are no. (%) of patients, unless otherwise indicated. IQR, interquartile range; SD, standard
deviation.
a Mupirocin 5/5 days and body wash 3/3 days.
b Minimum of mupirocin 4/5 days and body wash 3/3 days.
c Minimum of mupirocin 4/5 days and body wash 2/3 days.
d Minimum of mupirocin 3/5 days and body wash 2/3 days.
mupirocin and body wash. In the hospital setting, previously
reported institutional adherence estimates range from mod-
erately high (75%) to relatively low (37%), similar to our
patient-reported adherence in the outpatient setting.4,7 This
is the first observational study describing patient-reported
adherence to outpatient preoperative MRSA decolonization
therapy based on our review of the literature.
Colonization persistence and postoperative MRSA infec-
tions did not vary by adherence, although our study popu-
lation was small, with few follow-up MRSA infections, im-
pacting our ability to detect significant differences between
adherent and nonadherent patients. Our findings are also
limited by the incomplete data on mupirocin susceptibilities
since colonization persistence was observed in 80% of patients
with mupirocin-resistant MRSA. Adherence may have been
underestimated due to recall. Providing patients a formal day-
by-day decolonization therapy checklist to be returned on the
day of surgery may improve recall and adherence.
In conclusion, despite comprehensive education, patient-
reported adherence to preoperative MRSA decolonization
therapy was low (31.1%) in the outpatient setting. While
MRSA infections and colonization persistence were similar
between adherent and nonadherent outpatients, adherence
may affect therapy effectiveness and should be considered by
those implementing similar preoperative MRSA decoloniza-
tion programs.
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Impact of PCR Testing for Clostridium
difficile on Incident Rates and Potential on
Public Reporting: Is the Playing Field Level?
To the Editor—Healthcare-associated infections are a chal-
lenge to the healthcare field that pose an impact on the out-
comes of patients. Preventive measures are implemented at
most healthcare institutions to minimize the risks of acquiring
healthcare-associated infections.1 Clostridium difficile is a fas-
tidious anaerobic organism that is primarily responsible for
antibiotic-associated colitis and accounts for about one-quar-
ter of nosocomial antibiotic-associated diarrhea.2 In response
to a recognized increase in disease activity and severity, the
Ohio Department of Health made C. difficile infection (CDI)
a reportable disease in 2006,3 and it was reinstated under the
revised House Bill 197 in August 2010. While the benefits to
transparency are numerous, the downside is that rates will
be used for interhospital comparison, despite lack of adjust-
ment for case mix.4 The intersection of public reporting for
CDI in Ohio and the advent of testing based on polymerase
chain reaction (PCR) adds another layer of complexity. On
October 19, 2010, the Cleveland Clinic changed testing from
enzyme immunoassay to a PCR test for C. difficile detection.
We sought to compare our CDI rates before and after the
institution of PCR-based testing and evaluate the effect this
will have on our mandate for public reporting.
CDI surveillance is performed prospectively at the Cleve-
land Clinic by infection preventionists. Cases are ascertained
by daily review of lab reports of patients with positive stool
tests for C. difficile, and chart review establishes the presence
and onset of symptoms. Before October 19, 2010, testing was
performed by enzyme immunoassay detection of toxins A
and B (Wampole), and after this date, the testing methodology
was changed to PCR (BD Genehom). Query of the micro-
biology information systems was done to compare the results
of testing for CDI, using consecutive stool samples during a
3-month period before and after the change. A telephone
survey of 11 other Ohio hospitals was conducted to determine
whether PCR testing for CDI had been implemented at their
institution.
The prevalence of positive tests for CDI increased signif-
icantly from 6.5% of 2,579 stools tested to 15.1% of 2,534
stools tested after introduction of PCR testing ( ). TheP ! .001
rate of CDI also increased significantly (from 4.9 per 10,000
patient-days to 10.3; Table 1). There was no identified C.
difficile cluster after implementation of PCR testing to account
for the increased percent positives observed. None of the 11
hospitals in Ohio contacted had introduced PCR testing for
CDI during this time. There was a significant increase in the
number and rates of CDI after the introduction of PCR testing
that was unexplained by other reasons and not unexpected.
Decisions about choice of diagnostic platform for CDI testing
are complex and should not be driven by need for publicly
reporting rates. However, public display of CDI rates are an
implicit comparison of quality of care provided. In the case
of CDI, identifying test methods should be included.
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